Multi-Cancer Early Detection Blood Tests
I Tried the Next Frontier in Cancer Screening. I'm Dubious - Business Insider
What Patients and Caregivers Need to Know in 2026
Informed Prostate Cancer Support Group Newsletter
Bottom Line Up Front (BLUF):
The Promise: A Single Blood Test for Many Cancers
Cancer early detection remains one of oncology's holy grails. Most of us know the familiar screening tests—colonoscopies for colon cancer, mammograms for breast cancer, CT scans for lung cancer. But approximately 70% of U.S. cancer deaths occur from cancers with no established screening program: pancreatic, ovarian, esophageal, liver, stomach, and head-and-neck cancers, among others. These "orphan" cancers are typically discovered late, when treatment options narrow and outcomes worsen.
Multi-cancer early detection (MCED) blood tests propose a fundamentally different approach. Rather than screening for one cancer type at a time, they analyze a small sample of blood for circulating tumor DNA (ctDNA)—fragments of cancer-derived genetic material that leak into the bloodstream when tumors grow. Using sophisticated machine learning algorithms, these tests look for methylation patterns (epigenetic changes) in this cell-free DNA to detect cancer signals and predict which organ the cancer is coming from.
The appeal is obvious: a simple blood draw instead of colonoscopies, mammograms, or chest CT scans. One test instead of many. The ability to catch rare and ordinarily screened-for cancers earlier, when treatment is most effective.
The State of the Science: What We Know (and Don't Know)
Galleri: The Most Advanced Test
Grail Inc.'s Galleri test is the furthest along in clinical validation. The company has submitted a premarket approval (PMA) application to the FDA as of January 29, 2026, with a Breakthrough Device Designation granted in 2018. The FDA submission is supported by two major datasets:
Other Tests in Development
Several companies are pursuing MCED tests, though data are less mature:
- Cancerguard (Exact Sciences): Reports sensitivity of 50.9–62.3% and specificity of 98.5–99.1% in ongoing ASCEND-2 and DETECT-A trials. Not yet commercially available for general population screening.
- Shield (Guardant Health): Currently FDA-approved only for colorectal cancer screening (not multi-cancer). Sensitivity around 83% for colon cancer. Being evaluated in the National Cancer Institute's Vanguard Feasibility Study.
- ClearNote's Avantect: Also selected for NCI's Vanguard study; limited published data in general population screening.
The Real-World Performance Picture: Wins and Concerns
What the Tests Can Do Well
- Detect cancers that slip through conventional screening: In PATHFINDER 2, more than 70% of detected cancers were types without USPSTF-recommended screening. These include ovarian, pancreatic, stomach, liver, and head-and-neck cancers.
- Find some early-stage disease: The NHS trial showed a substantial increase in absolute numbers of stage I-II cancers in 12 high-mortality cancer types.
- Reduce emergency presentations: Fewer cancers were detected through emergency department visits, which are associated with worse outcomes and higher costs.
- Provide rapid origin prediction: Cancer signal origin (CSO) accuracy of 92–97% in PATHFINDER studies means most positive tests lead to efficient, focused diagnostic workup rather than fishing expeditions.
Real Limitations: The Caveats You Must Understand
Cost and Access: Who Can Afford These?
MCED tests remain expensive and out-of-pocket:
| Test | Current Cost | Insurance Coverage |
|---|---|---|
| Galleri (Grail) | $800–$950 (discounts available via Hims, Superpower) | Not currently covered by Medicare or most private plans |
| Cancerguard (Exact Sciences) | $690 | Not yet commercially available; under study |
| Shield (Guardant) | $1,495 (colorectal only, initially) | Approved via Advanced Diagnostic Laboratory Test (ADLT) pathway |
Medicare Coverage Coming in 2028
A major legislative win: On February 3, 2026, President Trump signed the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act into law. This allows Medicare to cover FDA-approved MCED tests beginning January 1, 2028, with age-phased eligibility (starting at age 68 in 2028, increasing by one year annually). Coverage is limited to one test every 11 months. However, this requires FDA approval first—no MCED test is FDA-approved yet. Grail's PMA application is under review; approval timeline is uncertain.
What Medical Organizations Actually Recommend
American Cancer Society
The American Cancer Society does not recommend MCED tests for routine screening, citing insufficient evidence. However, they acknowledge:
- Tests do not replace standard screening (mammograms, colonoscopies, etc.)
- Tests may complement standard screening or detect cancers without current screening options
- Much still needs to be learned about accuracy, harms, and clinical benefit
U.S. Preventive Services Task Force (USPSTF)
The USPSTF has not yet issued a formal recommendation on MCED tests. Their statement indicates that while the potential is promising, "no MCED test is currently approved by the FDA nor Centers for Medicare & Medicaid Services for reimbursement."
National Cancer Institute
The NCI is actively studying MCED tests in the Vanguard Feasibility Study (Shield and Avantect) to inform a future large-scale trial. This research is still underway; results will help shape future guidance.
For Patients With Cancer History: Emerging Data
One patient population that may benefit: cancer survivors. In December 2025, GRAIL published data showing that Galleri detected recurrences and second primary cancers in 1,609 cancer survivors enrolled in the PATHFINDER study. The test detected a cancer signal in 1.2% of survivors; 0.56% were ultimately diagnosed with cancer (9 of 1,609). This population may be a more appropriate use case than asymptomatic general screening, since survivors are already at elevated risk.
Prostate Cancer Considerations
MCED tests have specific limitations for prostate cancer patients and survivors:
- Prostate cancer is not included in the primary analysis of the NHS-Galleri trial because of concerns about overdiagnosis—detecting indolent prostate cancers that would never progress to clinical symptoms.
- PSA testing and MRI remain the standard for prostate cancer screening and surveillance.
- If you have advanced or metastatic prostate cancer, MCED might eventually help detect second primaries (lung, colon, pancreatic cancer), but this is not yet standard practice.
- If you have a history of prostate cancer, discuss with your oncologist whether adding an MCED test to your surveillance makes sense in your individual context—it is not routine care.
Should You Get an MCED Test? A Patient's Decision Framework
Consider It If:
- You are age 50–70, asymptomatic, with no cancer history
- You can afford $800–$950 out-of-pocket and understand you may need additional imaging if positive
- You want screening for cancers currently without standard options (pancreatic, ovarian, esophageal, liver, stomach)
- You are willing to accept 35–40% false-positive rate and understand the reassurance from a negative result is not absolute
- You understand that no MCED test has proven to improve survival or reduce cancer mortality yet
- Your doctor supports it as a complement to, not replacement for, standard screening
Do NOT Rely on It If:
- You are using it as an excuse to skip colonoscopies, mammograms, or other guideline-recommended screening
- You are expecting a 100% accurate diagnosis (the test requires follow-up imaging to confirm)
- You are experiencing cancer symptoms—get prompt diagnostic evaluation, not a screening test
- You are banking on a negative result to provide absolute reassurance (false negatives occur)
- You cannot afford the cost or the follow-up imaging if the result is positive
Red Flags: What We're Watching
- Premature marketing to patients without evidence: Some direct-to-consumer advertising emphasizes promise over demonstrated benefit. Be skeptical of claims that tests "save lives" without mortality data.
- Validation standards: Grail emphasizes that only prospectively validated tests (like Galleri) should be used clinically. Some competitors are making claims based on small, retrospective case-control studies—not adequate validation for screening.
- Overdiagnosis risk: If MCED tests become widespread, many indolent cancers (unlikely to cause symptoms or death) may be detected and treated unnecessarily, creating anxiety and harm without benefit.
- Cascade of testing: A positive MCED result can trigger expensive imaging (PET-CT, MRI) and invasive biopsies. Ensure you understand downstream costs and burdens before testing.
The Bottom Line
Multi-cancer early detection blood tests are a genuinely promising technology—one step closer to the cancer screening holy grail. The NHS-Galleri trial's findings on stage shifting and emergency presentation reduction are encouraging. FDA approval could be months away, and Medicare coverage in 2028 would expand access significantly.
But we are not there yet. No MCED test is FDA-approved. None has proven to reduce cancer mortality. False-positive and false-negative rates remain substantial. Tests are expensive and out-of-pocket today.
If you are considering an MCED test:
- Talk to your doctor first. Ask whether a test makes sense for your age, risk factors, and cancer history.
- Understand what a positive result means (not a diagnosis; requires follow-up imaging and possibly biopsy).
- Understand what a negative result means (reassuring but not absolute; standard screening still matters).
- Do not skip or delay guideline-recommended screening for breast, colon, cervical, and lung cancer.
- Stay informed as evidence evolves. Full NHS results and FDA decision are expected by summer 2026. That data will matter.
For now, these tests are a complementary tool—not a replacement for comprehensive, guideline-directed cancer care. Use them thoughtfully, with eyes wide open to both promise and limitation.
Verified Sources and Formal Citations
Comments
Post a Comment